StreetInsider.com News Articles

Form 6-K Pharming Group N.V. For: May 28

Thu, 28 May 2026 10:53:00 -0400

si-local-file:///var/storage/secattach/20260528/26563382.html

Form 6-K Pharming Group N.V. For: May 28

Thu, 28 May 2026 10:53:00 -0400

si-local-file:///var/storage/secattach/20260528/26563382.html

Form 6-K Pharming Group N.V. For: May 28

Thu, 28 May 2026 10:53:00 -0400

si-local-file:///var/storage/secattach/20260528/26563382.html

Form 6-K Pharming Group N.V. For: May 22

Fri, 22 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26542113.html

Form 6-K Pharming Group N.V. For: May 22

Fri, 22 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26542113.html

Form 6-K Pharming Group N.V. For: May 22

Fri, 22 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260522/26542113.html

Pharming Group (PHAR) PT Lowered to $40 at Oppenheimer

Fri, 08 May 2026 08:14:37 -0400

Oppenheimer lowered its price target on Pharming Group (NASDAQ: PHAR) to $40.00 (from $41.00) while maintaining a Outperform rating.

Canaccord Starts Pharming Group (PHAR) at Buy, PT $37

Fri, 10 Apr 2026 05:19:43 -0400

Canaccord analyst Whitney Ijem initiates coverage on Pharming Group (NASDAQ: PHAR) with a Buy rating and a price target of $37.00.

For an analyst ratings summary and ratings history on Pharming Group click here. For more ratings news on Pharming Group click here.

Shares of Pharming Group closed at $16.98 yesterday.

Canaccord Starts Pharming Group (PHAR) at Buy, PT $37

Fri, 10 Apr 2026 05:19:43 -0400

Canaccord analyst Whitney Ijem initiates coverage on Pharming Group (NASDAQ: PHAR) with a Buy rating and a price target of $37.00.

For an analyst ratings summary and ratings history on Pharming Group click here. For more ratings news on Pharming Group click here.

Shares of Pharming Group closed at $16.98 yesterday.

Pharming Group (PHAR) PT Lowered to $41 at Oppenheimer

Fri, 13 Mar 2026 08:28:29 -0400

Oppenheimer lowered its price target on Pharming Group (NASDAQ: PHAR) to $41.00 (from $42.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value"

Thu, 12 Mar 2026 11:53:50 -0400

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $37.00 price target on Pharming Group (NASDAQ: PHAR)

The analyst commented, "Commercial durability remains a big part of the story, with Ruconest continuing to add patients despite increasing competition in HAE and Joenja uptake supporting steady growth. The most important near-term catalyst, in our opinion, is the upcoming Type A meeting with the FDA following the pediatric Joenja CRL, which should clarify whether existing PK/exposure data can address questions around lower pediatric dosing and define the regulatory path forward. We expect 2026 to be characterized by continued commercial growth alongside longer-term

Form 6-K Pharming Group N.V. For: Mar 12

Thu, 12 Mar 2026 06:46:00 -0400

si-local-file:///var/storage/secattach/20260312/26148992.html

Form 6-K Pharming Group N.V. For: Mar 12

Thu, 12 Mar 2026 06:46:00 -0400

si-local-file:///var/storage/secattach/20260312/26148992.html

Form 6-K Pharming Group N.V. For: Mar 12

Thu, 12 Mar 2026 06:46:00 -0400

si-local-file:///var/storage/secattach/20260312/26148992.html

Form 6-K Pharming Group N.V. For: Feb 03

Tue, 03 Feb 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260203/25933883.html

Form 6-K Pharming Group N.V. For: Feb 03

Tue, 03 Feb 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260203/25933883.html

Form 6-K Pharming Group N.V. For: Feb 03

Tue, 03 Feb 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260203/25933883.html

Form 6-K Pharming Group N.V. For: Feb 01

Mon, 02 Feb 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260202/25927145.html

Form 6-K Pharming Group N.V. For: Feb 01

Mon, 02 Feb 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260202/25927145.html

Form 6-K Pharming Group N.V. For: Feb 01

Mon, 02 Feb 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260202/25927145.html

Form 6-K Pharming Group N.V. For: Jan 08

Thu, 08 Jan 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260108/25822680.html

Form 6-K Pharming Group N.V. For: Jan 08

Thu, 08 Jan 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260108/25822680.html

Form 6-K Pharming Group N.V. For: Jan 08

Thu, 08 Jan 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260108/25822680.html

Pharming Group reports preliminary 2025 revenues and announces Investor Day

Thu, 08 Jan 2026 01:00:00 -0400

Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).

Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the

Pharming Group reports preliminary 2025 revenues and announces Investor Day

Thu, 08 Jan 2026 01:00:00 -0400